JP4948418B2 - Ｎｋｔ細胞を抑制するための方法 - Google Patents

Ｎｋｔ細胞を抑制するための方法 Download PDF

Info

Publication number
JP4948418B2
JP4948418B2 JP2007539372A JP2007539372A JP4948418B2 JP 4948418 B2 JP4948418 B2 JP 4948418B2 JP 2007539372 A JP2007539372 A JP 2007539372A JP 2007539372 A JP2007539372 A JP 2007539372A JP 4948418 B2 JP4948418 B2 JP 4948418B2
Authority
JP
Japan
Prior art keywords
cells
composition
administration
galactosylceramide
nkt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007539372A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008518974A (ja
JP2008518974A5 (enExample
Inventor
サミュエル ストローバー，
エベレット ハートー マイヤー，
デール ティー． ウメツ，
Original Assignee
ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ filed Critical ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ
Publication of JP2008518974A publication Critical patent/JP2008518974A/ja
Publication of JP2008518974A5 publication Critical patent/JP2008518974A5/ja
Application granted granted Critical
Publication of JP4948418B2 publication Critical patent/JP4948418B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2007539372A 2004-11-02 2005-11-02 Ｎｋｔ細胞を抑制するための方法 Expired - Fee Related JP4948418B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US62456804P 2004-11-02 2004-11-02
US60/624,568 2004-11-02
US70654805P 2005-08-08 2005-08-08
US60/706,548 2005-08-08
PCT/US2005/040182 WO2006060117A2 (en) 2004-11-02 2005-11-02 Methods for inhibition of nkt cells

Publications (3)

Publication Number Publication Date
JP2008518974A JP2008518974A (ja) 2008-06-05
JP2008518974A5 JP2008518974A5 (enExample) 2008-11-27
JP4948418B2 true JP4948418B2 (ja) 2012-06-06

Family

ID=36565493

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007539372A Expired - Fee Related JP4948418B2 (ja) 2004-11-02 2005-11-02 Ｎｋｔ細胞を抑制するための方法

Country Status (11)

Country Link
US (2) US7682614B2 (enExample)
EP (1) EP1812015B1 (enExample)
JP (1) JP4948418B2 (enExample)
CN (1) CN101031307B (enExample)
AT (1) ATE539757T1 (enExample)
AU (1) AU2005310247A1 (enExample)
CA (1) CA2584971C (enExample)
DK (1) DK1812015T3 (enExample)
ES (1) ES2378076T3 (enExample)
PT (1) PT1812015E (enExample)
WO (1) WO2006060117A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002254396A1 (en) 2001-03-26 2002-10-08 Dana-Farber Cancer Institute, Inc. Method of attenuating reactions to skin irritants
EP2575824A4 (en) * 2010-05-24 2014-02-19 Childrens Medical Center METHOD FOR THE TREATMENT AND PREVENTION OF INFLAMMATORY DISEASES
DK2643346T3 (en) * 2010-11-25 2018-10-29 Imnate Sarl MODULATION OF ANTIGEN IMMUNOGENICITY BY ADDITION OF EPITOPES RECOGNIZED BY NKT CELLS
EP2731617A4 (en) 2011-07-12 2015-07-01 Brigham & Womens Hospital LIPID-BASED PSA COMPOSITIONS, METHOD FOR THEIR INSULATION AND USE METHOD THEREFOR
CN103945867B (zh) * 2011-10-27 2018-01-02 Nkt治疗公司 针对iNKT的人类化抗体
EP2906576B1 (en) 2012-10-12 2019-09-11 The Brigham and Women's Hospital, Inc. Glycosphingolipids and methods of use thereof
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
CA2910766C (en) 2013-04-30 2020-12-15 Otitopic Inc. Dry powder formulations and methods of use
JP6743051B2 (ja) 2015-01-27 2020-08-19 ラヴァ・セラピューティクス・ベー・フェー Ｃｄ１ｄを標的とする単一ドメイン抗体
CN108135167B (zh) 2015-08-19 2021-07-09 哈佛学院院长及董事 脂化psa组合物和方法
EP3484441A4 (en) 2016-07-15 2020-03-18 President and Fellows of Harvard College GLYCOLIPID COMPOSITIONS AND METHOD FOR USE
WO2019059953A2 (en) 2017-09-22 2019-03-28 Otitopic Inc. DRY POWDER COMPOSITIONS CONTAINING MAGNESIUM STEARATE
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
EP3853255A1 (en) 2018-09-19 2021-07-28 Lava Therapeutics B.V. Novel bispecific antibodies for use in the treatment of hematological malignancies
IL305579A (en) 2021-03-01 2023-10-01 Deciduous Therapeutics Inc Compounds for activating invariant natural killer T cells and methods for use in eliminating inflammatory senescent cells
EP4480486A1 (en) * 2022-02-14 2024-12-25 Riken Nkt cell ligand-containing liposome composition

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6800738B1 (en) * 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
US7063844B2 (en) * 1992-12-10 2006-06-20 The Brigham And Women's Hospital, Inc. Presentation of hydrophobic antigens to T-cells by CD1 molecules
US5679347A (en) * 1992-12-10 1997-10-21 Brigham And Women's Hospital Methods of isolating CD1-presented antigens, vaccines comprising CD1-presented antigens, and cell lines for use in said methods
DE69433115T2 (de) 1993-06-21 2004-04-01 Brigham And Women's Hospital, Boston Verfahren zur isolierung von cda-präsentierten antigenen, cd1-präsentierte antigeneenthaltende impfstoffe und in besagten verfahren verwendbare zelllinien
US6632976B1 (en) * 1995-08-29 2003-10-14 Kirin Beer Kabushiki Kaisha Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene
ATE421881T1 (de) * 1997-04-10 2009-02-15 Kyowa Hakko Kirin Co Ltd Nkt-zellenaktivatoren, die alpha-glycosylceramide enthalten
EP1011719A1 (en) * 1997-09-12 2000-06-28 Brigham & Women's Hospital Synthetic antigens for cd1-restricted immune responses
TW575420B (en) * 1997-09-22 2004-02-11 Kirin Brewery Composition for enhancing cellular immunogenicity comprising alpha-glycosylceramides
US6197582B1 (en) * 1998-03-18 2001-03-06 The Trustees Of Columbia University In The City Of New York Development of human monoclonal antibodies and uses thereof
AU4837499A (en) 1998-07-09 2000-02-01 Brian J. Nickoloff Method of treating disorders by modulating the interaction of natural killer receptors on t cells with their respective ligands
US20010051156A1 (en) * 2000-04-28 2001-12-13 Defu Zeng Methods for inhibition of polyclonal B cell activation and immunoglobulin class switching to pathogenic autoantibodies by blocking CD1-mediated interactions
WO2001094949A2 (en) 2000-06-05 2001-12-13 The Brigham And Women's Hospital, Inc. Soluble cd1 compositions and uses thereof
CN1444648A (zh) * 2000-06-06 2003-09-24 麒麟麦酒株式会社 扩增自然杀伤t细胞的方法
PT1297017E (pt) * 2000-06-19 2012-09-04 Gen Hospital Corp Composições e métodos de anticorpos monoclonais e policlonais específicos para subpopulações de célula t
US20020115624A1 (en) * 2000-06-22 2002-08-22 Behar Samuel M. Alpha gylcosylceramides for treating bacterial and fungal infections
WO2002016825A1 (fr) * 2000-08-18 2002-02-28 Mitsubishi Denki Kabushiki Kaisha Douille et transformateur pour lampe et procede de fabrication d'un transformateur pour lampe
DE10046658A1 (de) 2000-09-20 2002-04-04 Bosch Gmbh Robert Induktiver Übertrager und ein Verfahren zu dessen Herstellung
DE60131456T2 (de) * 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
IL140537A0 (en) * 2000-12-25 2002-02-10 Hadasit Med Res Service Educated nk t cells and their uses in the treatment of immune-related disorders
AU2002254396A1 (en) * 2001-03-26 2002-10-08 Dana-Farber Cancer Institute, Inc. Method of attenuating reactions to skin irritants
US6662434B2 (en) * 2001-04-03 2003-12-16 General Electric Company Method and apparatus for magnetizing a permanent magnet
US8178098B2 (en) * 2001-04-03 2012-05-15 National Jewish Health Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
CA2444429A1 (en) * 2001-04-11 2002-11-07 Atherogenics, Inc. Probucol monoesters and their use to increase plasma hdl cholesterol levels and improve hdl functionality
US20020171538A1 (en) * 2001-05-15 2002-11-21 Kuo-Hsin Su Vehicle motion detector and control device arrangement
US20020171557A1 (en) * 2001-05-18 2002-11-21 Wegener William E. Security electronic system
JP2005500336A (ja) * 2001-07-25 2005-01-06 ニューヨーク・ユニバーシティ 感染および癌に対するワクチンのためのアジュバントとしてのグリコシルセラミドの使用
AU2003234443A1 (en) 2002-05-01 2003-11-17 Beth Israel Deaconess Medical Center Use of anti-cd1 antibodies for the modulation of immune responses
US7273852B2 (en) * 2002-06-13 2007-09-25 The Research Foundation Of The City University Of New York Synthetic C-glycolipid and its use for treating cancer, infectious diseases and autoimmune diseases
DE60239566D1 (de) 2002-06-14 2011-05-05 Brigham And Women S Hospital Boston Verfahren zur behandlung und prävention von kolitis, an der il-13 und nk-t zellen beteiligt sind
US7368142B2 (en) * 2002-08-01 2008-05-06 Renew Life Formulas, Inc. Natural sweetener
JP2006511462A (ja) 2002-08-27 2006-04-06 ソシエテ デ プロデユイ ネツスル ソシエテ アノニム 上皮組織損傷又は脱毛症の予防又は治療
AU2003277021A1 (en) 2002-09-27 2004-04-19 Biomira, Inc. Glycosylceramide analogues
US9717754B2 (en) * 2003-02-27 2017-08-01 Enzo Therapeutics, Inc. Glucocerebroside treatment of disease
US20040171522A1 (en) * 2003-02-27 2004-09-02 Yaron Ilan Regulation of immune responses by manipulation of intermediary metabolite levels
WO2005032462A2 (en) 2003-02-27 2005-04-14 Enzo Therapeutics, Inc. Glucocerebroside treatment of disease
US20040235162A1 (en) * 2003-03-18 2004-11-25 Kirin Beer Kabushiki Kaisha Method of preparing immunoregulatory dendritic cells and the use thereof
US20050032210A1 (en) * 2003-03-18 2005-02-10 Kirin Beer Kabushiki Kaisha Method of preparing immuno-regulatory dendritic cells and the use thereof
AU2003225891A1 (en) 2003-03-20 2004-11-19 Brigham Young University 6"-amino-6"-deoxygalactosylceramides
WO2004084874A2 (en) 2003-03-24 2004-10-07 Brigham And Women's Hospital, Inc. Mtp inhibitors for inhibiting inflammation
EP1653977A2 (en) 2003-07-17 2006-05-10 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Treatment of disorders associated with natural killer t cells
AU2005251589B2 (en) * 2004-06-11 2011-01-06 Riken Drug having regulatory cell ligand contained in liposome

Also Published As

Publication number Publication date
EP1812015A2 (en) 2007-08-01
US7682614B2 (en) 2010-03-23
CN101031307B (zh) 2012-09-05
ATE539757T1 (de) 2012-01-15
US20100197613A1 (en) 2010-08-05
AU2005310247A1 (en) 2006-06-08
EP1812015A4 (en) 2008-02-20
WO2006060117A2 (en) 2006-06-08
EP1812015B1 (en) 2012-01-04
JP2008518974A (ja) 2008-06-05
ES2378076T3 (es) 2012-04-04
DK1812015T3 (en) 2013-01-02
US20060116332A1 (en) 2006-06-01
CA2584971C (en) 2013-08-06
US8679499B2 (en) 2014-03-25
CA2584971A1 (en) 2006-06-08
PT1812015E (pt) 2012-02-20
CN101031307A (zh) 2007-09-05
WO2006060117A3 (en) 2007-03-01

Similar Documents

Publication Publication Date Title
US8679499B2 (en) Methods for relieving asthma-associated airway hyperresponsiveness
JP6764396B2 (ja) 二糖合成脂質化合物およびその使用
Kim et al. Asthma is induced by intranasal coadministration of allergen and natural killer T-cell ligand in a mouse model
Agnihotri et al. Structure–activity relationships in Toll-like receptor 2-agonists leading to simplified monoacyl lipopeptides
US20180105547A1 (en) Methods for the treatment and prevention of inflammatory diseases
US20240076393A1 (en) Regulating il-4 and il-13 levels by blocking high affinity binding by il-3, il-5 and gm-csf to their common receptor
JP4804626B2 (ja) 免疫レギュレータ
Chaby Strategies for the control of LPS-mediated pathophysiological disorders
Xu et al. Low and high doses of ursolic acid ameliorate experimental autoimmune myasthenia gravis through different pathways
JP2009520730A (ja) アレルギー性疾患を治療および予防するための手段および方法
US20100204295A1 (en) Treatment of allergic disease with immunomodulator compounds
AU2011250800B2 (en) Methods for inhibition of NKT cells
WO2009135001A2 (en) Methods and compositions for regulating th2 and th17 responses
WO2016144760A1 (en) Compositions and methods for treating allergic inflammation
US20100035843A1 (en) Methods for attenuating allergen-induced airway hyperreactivity using cd1d dependent antagonists
US20130281409A1 (en) Myelin Sheath Fatty Acids that Resolve Neuroinflammation
WO2009015279A2 (en) Agents and methods for inhibition of airway hyperresponsiveness
Van Rensburg Immunoactive, Antibacterial and Drug-Carrying properties of selective surfactants

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081006

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081006

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110608

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110906

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110913

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111011

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111018

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111031

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120216

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120306

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150316

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees